New drug shows promise for rare skin cancers
NCT ID NCT07132567
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is tracking how safe and effective the drug mogamulizumab (Poteligeo) is for adults with two rare types of skin lymphoma: mycosis fungoides and Sézary syndrome. Researchers will monitor 15 participants in routine care settings for side effects and how well the drug controls the disease. The goal is to see if the drug works in real-world use, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mogamulizumab (Poteligeo)
What this could lead to
If successful, this could confirm that mogamulizumab works well and is safe for treating these rare skin lymphomas in everyday medical practice.
What could go wrong
This is a small, observational study with only 15 participants, so results may not apply to all patients. Side effects are possible, and the drug is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chung-Ang University Hospital
TERMINATEDSeoul, South Korea
-
Ewha Womans University Mokdong Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kosin University Gospel Hospital
RECRUITINGBusan, Busan Metropolitan City, 49267, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact